HKSE - Delayed Quote HKD
Simcere Pharmaceutical Group Limited (2096.HK)
At close: October 22 at 4:08 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
6,607,805.000
6,607,805.000
6,324,082.000
4,999,718.000
4,508,720.000
--
Cost of Revenue
1,623,652.000
1,623,652.000
1,327,404.000
1,079,983.000
899,927.000
--
Gross Profit
4,984,153.000
4,984,153.000
4,996,678.000
3,919,735.000
3,608,793.000
--
Operating Expense
4,257,652.000
4,257,652.000
4,422,047.000
3,687,923.000
3,018,910.000
--
Operating Income
726,501.000
726,501.000
574,631.000
231,812.000
589,883.000
--
Net Non Operating Interest Income Expense
20,392.000
20,392.000
25,459.000
-2,561.000
-107,481.000
--
Pretax Income
740,038.000
740,038.000
886,254.000
1,401,797.000
805,088.000
--
Tax Provision
26,088.000
26,088.000
-40,478.000
-97,124.000
140,801.000
--
Net Income Common Stockholders
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
--
Diluted NI Available to Com Stockholders
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
--
Basic EPS
0.27
0.27
0.36
0.58
0.26
--
Diluted EPS
0.27
0.27
0.36
0.58
0.26
--
Basic Average Shares
2,608,533.908
2,608,533.908
2,611,171.592
2,608,641.618
2,608,641.618
--
Diluted Average Shares
2,608,533.908
2,608,533.908
2,620,375.892
2,611,357.884
2,608,641.618
--
Total Operating Income as Reported
711,802.000
711,802.000
860,605.000
1,448,544.000
926,836.000
--
Total Expenses
5,881,304.000
5,881,304.000
5,749,451.000
4,767,906.000
3,918,837.000
--
Net Income from Continuing & Discontinued Operation
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
--
Normalized Income
721,018.354
721,018.354
686,779.750
930,408.250
361,642.164
--
Interest Income
54,960.000
54,960.000
59,867.000
68,287.000
26,248.000
--
Interest Expense
34,568.000
34,568.000
34,408.000
70,848.000
133,729.000
--
Net Interest Income
20,392.000
20,392.000
25,459.000
-2,561.000
-107,481.000
--
EBIT
774,606.000
774,606.000
920,662.000
1,472,645.000
938,817.000
--
EBITDA
1,084,200.000
1,084,200.000
1,204,309.000
1,724,452.000
1,161,146.000
--
Reconciled Cost of Revenue
1,623,652.000
1,623,652.000
1,327,404.000
1,079,983.000
899,927.000
--
Reconciled Depreciation
309,594.000
309,594.000
283,647.000
251,807.000
222,329.000
--
Net Income from Continuing Operation Net Minority Interest
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
--
Total Unusual Items Excluding Goodwill
-6,486.000
-6,486.000
325,451.000
768,917.000
373,152.000
--
Total Unusual Items
-6,486.000
-6,486.000
325,451.000
768,917.000
373,152.000
--
Normalized EBITDA
1,090,686.000
1,090,686.000
878,858.000
955,535.000
787,994.000
--
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
--
Tax Effect of Unusual Items
-228.646
-228.646
81,362.750
192,229.250
65,260.164
--
12/31/2019 - 10/27/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2005.HK SSY Group Limited
3.830
-0.52%
1558.HK YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
9.080
+0.78%
2552.HK Hua Medicine (Shanghai) Ltd.
1.540
+0.65%
2186.HK Luye Pharma Group Ltd.
3.060
-0.97%
1349.HK Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
2.890
-1.70%
0512.HK Grand Pharmaceutical Group Limited
4.710
+0.64%
3692.HK Hansoh Pharmaceutical Group Company Limited
20.650
-2.59%
1513.HK Livzon Pharmaceutical Group Inc.
28.400
+1.43%
2877.HK China Shineway Pharmaceutical Group Limited
9.740
+2.10%
3933.HK The United Laboratories International Holdings Limited
10.800
+1.31%